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Increasing number and heterogeneity of cancer 
genes
Recent  advances  in  sequencing  technologies  and  the 
launching of massive resequencing projects such as the 
Cancer Genome Project [1] have boosted the production 
of cancer genomics data. In the past few years, the entire 
repertoire of human exons has been sequenced in glio­
blastoma  [2],  pancreatic  [3],  breast  and  colorectal  [4] 
cancers, and somatic mutations in selected genes have 
been mapped in multiple samples of renal [5] and lung 
[6] adenocarcinomas. In addition, the whole genomes of 
individuals  affected  by  leukemia  [7,8],  melanoma  [9], 
glioma [10], breast [11,12], and lung [13] cancers have 
been fully resequenced. All these studies have led to the 
identification of more than 1,000 potential cancer genes, 
and the list is likely to grow in the near future.
This massive amount of information will have a huge 
impact  on  our  understanding  of  cancer  genetics,  even 
more  so  considering  that  the  biological  role  of  most 
mutations is still obscure. These first unbiased screenings 
have led to the identification of novel and unsuspected 
determinants of cancer, such as the isocitrate dehydro­
genase enzyme genes IDH1 and IDH2, which have been 
found mutated in glioblastoma multiforme [2]. They have 
also  started  to  question  some  cornerstones  of  cancer 
biology,  such  as  the  description  of  cancer  as  a  unique 
disease driven by the somatic modification of a few key 
regulators.  The  progressive  identification  of  novel 
mutated genes is expanding the ‘cast of actors’ [14] whose 
mutations might be causally involved in driving cancer. 
Moreover, given the high heterogeneity of genes mutated 
in different cancer types (Figure 1), the overall ‘plot’ is 
becoming more intricate. The emerging picture suggests 
that  there  may  be  distinct  genetic  routes  to  reach  the 
common aftermath of all tumorigenic processes, which is 
uncontrolled cell proliferation. For example, as many as 
12  core  pathways  are  disrupted  in  the  majority  of 
pancreatic cancers through multiple somatic mutations 
[3].  This  opens  up  an  intriguing  scenario  where  the 
deregulation  of  key  pathways  for  tumorigenesis  repre­
sents only the final step of a more general perturbation of 
cellular activity. The cell is seen as an integrated system in 
which  all  processes  form  a  tightly  interconnected 
network  more  than  as  an  ensemble  of  independent 
pathways. In this context, the effect of somatic mutations 
occurring in the cancer genome should be interpreted in 
the  light  of  their  broader  impact  on  the  system’s 
equilibrium.
Cancer is a disease of multicellular organisms, where 
each  cell  is  integrated  within  the  larger  system  of  the 
whole  organism.  In  a  recent  paper  in  BMC  Biology, 
Domazet­Lošo  and  Tautz  [15]  trace  the  evolutionary 
origins of known cancer genes and find that in most cases 
the  origins  coincide  with  one  of  two  pivotal  events  in 
evolution ­ the emergence of the first cell or the transition 
towards metazoan multicellularity.
Systems-level perturbations of cancer-related 
mutations
The  first  attempts  to  study  cancer  genes  using  more 
systematic approaches have already proved successful in 
broadening our knowledge of the genetic determinants of 
cancer.  A  multidimensional  analysis  has  combined 
sequence  similarity,  functional  annotations,  protein­
protein interactions, and molecular pathways to examine 
genes mutated in breast and colorectal cancers [16]. This 
study  showed  that  while  processes  involved  with 
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http://www.biomedcentral.com/1741-7007/8/74Figure 1. Heterogeneity of genes mutated in different cancer 
types. So far, more than 1,000 human genes have been identified 
that carry proven or potential driver mutations involved in cancer 
progression. Of those, only 85 genes have been found mutated in at 
least two studies, either in large-scale screenings or in the cancer gene 
census, which is a literature-based collection of known cancer genes 
[20]. The latter can be genetically repressive (red) or dominant (orange), 
which broadly correspond to tumor-suppressors and caretakers and 
to oncogenes, respectively. This distinction cannot be done for genes 
identified through large-scale screenings that involve either massive 
exon [2-6] or whole-genome [7-13] resequencing. NTRK1
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Page 2 of 4intracellular signaling, control of the cell cycle and meta­
bo  lism are modified in both tumors, most pathways are 
instead  specific  to  one  of  the  two,  suggesting  that 
different molecular mechanisms underlie these two types 
of tumors [16].
In the context of systems­biology approaches, methods 
that examine protein­protein interactions are particularly 
informative because they evaluate the effect of mutations 
on  the  complex  network  of  cellular  interconnections. 
Topological  analyses  of  the  human  protein­protein 
interaction  network  reveal  that  known  and  candidate 
cancer genes encode central hubs ­ that is, proteins that 
engage several connections and occupy central positions 
at the crossroads of multiple biological processes [17,18]. 
Our  analysis  [18]  also  reveals  that  paralogs  of  cancer 
genes  (that  is,  genes  related  by  duplication)  are  less 
common  than  for  other  genes,  which  indicates  a 
sensitivity of cancer genes to dosage modification.
All these properties are uncommon within the human 
gene  repertoire  and  help  to  interpret  the  incidence  of 
somatic  mutations  as  a  sign  of  a  broader  fragility  of 
cancer genes towards any type of perturbation. Deletions, 
mutations  and  amplifications  of  highly  interconnected 
genes are likely to be deleterious because they can affect 
several  aspects  of  the  cell’s  life.  Interestingly,  we  have 
found that these properties are not limited to well­known 
cancer  genes  but  are  also  shared  by  genes  whose 
modifications  have  been  identified  through  large­scale 
mutational screenings [19]. Again, this shows that there 
are common features of cancer genes, not immediately 
apparent  from  their  individual  function,  but  seen  at  a 
systems  level,  that  help  explain  their  role  in  tumor 
development.
Evolutionary origin of cancer genes
The newest piece of evidence that confirms how useful 
the global analysis of cancer genes can be is reported by 
Domazet­Lošo and Tautz [15], who analyze the origin of 
founder  domains  of  known  cancer  proteins.  Using  a 
methodology  called  ‘genomic  phylostratigraphy’,  the 
authors are able to trace when the most conserved por­
tions of known cancer proteins, which often correspond 
to  functional  domains,  appeared  in  evolution.  They 
observe two peaks, one at the origin of the ancestral cell 
and the other at the origin of metazoans.
Interestingly,  these  two  peaks  are  enriched  in  two 
distinct  groups  of  genes,  namely  ‘caretakers’  and 
‘gatekeepers’, that contribute to cancer through different 
mechanisms. Caretakers are associated with the origin of 
the first cell and are involved in the control of genome 
stability  and  their  modification  increases  the  mutation 
rate  and  favors  genomic  instability.  Gatekeepers  origi­
nated with metazoans and their modifications directly or 
indirectly  affect  cell  differentiation,  growth  and  death. 
The different evolutionary origins of these genes suggest 
two  distinct  mechanisms  of  carcinogenesis.  The  first 
deals  with  the  basic  functions  of  the  cell,  such  as  the 
control of genome stability, that, very reasonably, were 
established already in the ancestral eukaryotic cell. The 
second  mechanism  is  intimately  connected  to 
multicellularity  and  to  the  interactions  between  cells 
within a complex organism. This observation puts cancer 
in the context of macroevolutionary transitions and links 
tumorigenesis  to  the  disruption  of  processes  that  are 
essential for survival of the cell and for its communication 
with the external environment.
The  emerging  heterogeneity  of  the  cancer  genomic 
landscape has been used to question the usefulness of 
large­scale screenings, the main concern being that the 
discovery of rare mutations adds very little to the overall 
knowledge of cancer genetics. Approaches that focus on 
the  identification  of  global  features,  more  than  to  the 
study of single genes, show instead that a comprehensive 
catalogue of cancer genetic determinants is instrumental 
to  trace  recurrent  patterns  in  their  systems­level  and 
evolutionary properties.
Acknowledgements
The author thanks Matteo D’Antonio and Adnan Syed for help with the figure. 
The author is supported by the Start-Up grant of the Italian Association for 
Cancer Research (AIRC).
Published: 11 June 2010
References
1.  The International Cancer Genome Project [http://www.icgc.org]
2.  Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter 
H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, 
Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg 
RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, 
Papadopoulos N, Parmigiani G, et al.: An integrated genomic analysis of 
human glioblastoma multiforme. Science 2008, 321:1807-1812.
3.  Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter 
H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, 
Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, 
Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, 
Kern SE, Hruban RH, et al.: Core signaling pathways in human pancreatic 
cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
4.  Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, 
Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, 
Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, 
Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda 
CL, Pant PV, et al.: The genomic landscapes of human breast and colorectal 
cancers. Science 2007, 318:1108-1113.
5.  Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, 
Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck 
G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin 
ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, 
et al.: Systematic sequencing of renal carcinoma reveals inactivation of 
histone modifying genes. Nature 2010, 463:360-363.
6.  Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, 
Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, 
Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, 
Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc 
K, et al.: Somatic mutations affect key pathways in lung adenocarcinoma. 
Nature 2008, 455:1069-1075.
7.  Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-
Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt 
Ciccarelli BMC Biology 2010, 8:74 
http://www.biomedcentral.com/1741-7007/8/74
Page 3 of 4DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, 
Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, 
et al.: DNA sequencing of a cytogenetically normal acute myeloid 
leukaemia genome. Nature 2008, 456:66-72.
8.  Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, 
Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, 
Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, 
Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, 
Brummett AM, Clark E, McMichael JF, et al.: Recurring mutations found by 
sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 
361:1058-1066.
9.  Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, 
Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer 
MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, 
Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, 
Kingsbury Z, Leroy C, Marshall J, Menzies A, et al.: A comprehensive 
catalogue of somatic mutations from a human cancer genome. Nature 
2010, 463:191-196.
10.  Clark MJ, Homer N, O’Connor BD, Chen Z, Eskin A, Lee H, Merriman B, Nelson 
SF: U87MG decoded: the genomic sequence of a cytogenetically aberrant 
human cancer cell line. PLoS Genet 2010, 6:e1000832.
11.  Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, 
Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore 
R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren 
RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S: 
Mutational evolution in a lobular breast tumour profiled at single 
nucleotide resolution. Nature 2009, 461:809-813.
12.  Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, 
Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, 
Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, 
McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin 
L, et al.: Genome remodelling in a basal-like breast cancer metastasis and 
xenograft. Nature 2010, 464:999-1005.
13.  Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, Lin 
ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordoñez 
GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall 
J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA, McLaughlin SF, 
Peckham HE, Tsung EF, et al.: A small-cell lung cancer genome with complex 
signatures of tobacco exposure. Nature 2010, 463:184-190.
14.  Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. 
Nat Med 2004, 10:789-799.
15.  Domazet-Loso T, Tautz D: Phylostratigraphic tracking of cancer genes 
suggests a link to the emergence of multicellularity in metazoa. BMC Biol 
2010, 8:66.
16.  Lin J, Gan CM, Zhang X, Jones S, Sjöblom T, Wood LD, Parsons DW, 
Papadopoulos N, Kinzler KW, Vogelstein B, Parmigiani G, Velculescu VE: 
A multidimensional analysis of genes mutated in breast and colorectal 
cancers. Genome Res 2007, 17:1304-1318.
17.  Jonsson PF, Bates PA: Global topological features of cancer proteins in the 
human interactome. Bioinformatics 2006, 22:2291-2297.
18.  Rambaldi D, Giorgi FM, Capuani F, Ciliberto A, Ciccarelli FD: Low duplicability 
and network fragility of cancer genes. Trends Genet 2008, 24:427-430.
19.  Syed AS, D’Antonio M, Ciccarelli FD: Network of Cancer Genes: a web 
resource to analyze duplicability, orthology and network properties of 
cancer genes. Nucleic Acids Res 2010, 38:D670-D675.
20.  Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, 
Stratton MR: A census of human cancer genes. Nat Rev Cancer 2004, 
4:177-183.
doi:10.1186/1741-7007-8-74
Cite this article as: Ciccarelli FD: The (r)evolution of cancer genetics. BMC 
Biology 2010, 8:74.
Ciccarelli BMC Biology 2010, 8:74 
http://www.biomedcentral.com/1741-7007/8/74
Page 4 of 4